NCT07205601 · Phase 2 · NOT YET RECRUITING
Study of Intracerebroventricular Injections of Autologous Adipose-Derived Stem Cells (RB-ADSCs) in Participants With Mild-Moderate Alzheimer's Disease
This trial is testing whether repeated injections of a person's own fat-derived stem cells, delivered into the brain's fluid spaces every 2 months for 6 doses, improve thinking and memory compared with a placebo. It also tracks safety. It is a Phase 2 trial, meaning it is testing whether the approach works and is safe, not yet proven or approved.
You may qualify if
- ≥45 and ≤85 years of age
- Mild to moderate AD diagnosis
- FAST stage 4 or 5
- MMSE 10-23
- Amyloid PET scan centiloid score >30
- ADmark® CSF analysis of ATI (\<1.0) and P-Tau (>60)
- No tumors or other disease responsible for dementia
- Participant otherwise in good general health
- Written informed consent from participant or legal representative
- Participant must have caregiver who separately meets specified inclusion/exclusion criteria for caregivers
- Participant must be able to donate adequate amount of lipoaspirate to establish the final product
You're excluded if
- Taking prohibited medications
- Prior cell therapy implantation
- Existing ventriculoperitoneal shunts
- Neurological disorders except AD
- Psychiatric disorders such as schizophrenia, bipolar/unipolar depression, delirium
- Drug or alcohol abuse in past 2 years
- History of cancer within the past 5 years
- No caregiver available to meet the inclusion criteria for caregivers
- Involvement in other investigational product clinical trial within the past 3 months for monoclonal antibodies, or 6 months for other investigational products
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-08-26